Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)’s share price was down 0.5% on Wednesday . The stock traded as low as $3.80 and last traded at $3.79. Approximately 1,347,763 shares changed hands during mid-day trading, an increase of 16% from the average daily volume of 1,162,330 shares. The stock had previously closed at $3.81.

Several equities analysts have recently weighed in on MRNS shares. ValuEngine raised Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. JMP Securities reaffirmed an “outperform” rating and issued a $11.00 price objective (up from $5.00) on shares of Marinus Pharmaceuticals in a research note on Tuesday.

The stock’s market cap is $102.47 million. The firm’s 50-day moving average is $2.64 and its 200-day moving average is $1.72.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.06. On average, equities research analysts anticipate that Marinus Pharmaceuticals, Inc. will post ($0.74) earnings per share for the current fiscal year.

A number of hedge funds have recently modified their holdings of the business. Jennison Associates LLC increased its position in Marinus Pharmaceuticals by 108.1% in the 2nd quarter. Jennison Associates LLC now owns 811,665 shares of the biopharmaceutical company’s stock worth $1,112,000 after purchasing an additional 421,600 shares during the last quarter. Nexthera Capital LP acquired a new position in Marinus Pharmaceuticals in the 1st quarter worth about $1,416,000. Granite Point Capital Management L.P. acquired a new position in Marinus Pharmaceuticals in the 1st quarter worth about $1,372,000. Finally, KCG Holdings Inc. increased its position in Marinus Pharmaceuticals by 29.5% in the 1st quarter. KCG Holdings Inc. now owns 64,539 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 14,692 shares during the last quarter. 28.76% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/13/marinus-pharmaceuticals-inc-mrns-stock-price-down-0-5.html.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Receive News & Stock Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.